SCHEMBL27225016

SCHEMBL27225016

COc1ccc(CN2C(=O)CCC(n3c(=O)n(C)c4c(N5CCNCC5)cccc43)C2=O)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 4/20 0.42
▸ KMT2A Q03164 4/20 0.42
▸ LMNA P02545 1/20 0.42
▸ HTR3A P46098 2/20 0.40
▸ HCRTR1 O43613 2/20 0.38
▸ HCRTR2 O43614 2/20 0.38
▸ HTR6 P50406 3/20 0.38
▸ ALDH1A1 P00352 2/20 0.37
▸ HTR1A P08908 2/20 0.37
▸ GSK3B P49841 2/20 0.37
▸ HTR7 P34969 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ OPRM1 P35372 1/20 0.37
▸ L3MBTL1 Q9Y468 2/20 0.37
▸ POLB P06746 1/20 0.36
▸ BLM P54132 1/20 0.36
▸ TP53 P04637 1/20 0.35
▸ THRB P10828 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ GSK3A P49840 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27225261 0.90 MEN1 (0.41) MEN1KMT2ALMNAHCRTR1HCRTR2
Hydrochloric Acid SCHEMBL31161458 0.90 MEN1 (0.40) MEN1KMT2ALMNAHTR3AHCRTR1
SCHEMBL29751424 0.89 MEN1 (0.38) MEN1KMT2ALMNAHCRTR1HCRTR2
SCHEMBL24608116 0.89 MEN1 (0.38) MEN1KMT2ALMNAHCRTR1HCRTR2
SCHEMBL27224929 0.88 MEN1 (0.41) MEN1KMT2ALMNAHCRTR1HCRTR2
SCHEMBL27225524 0.88 MEN1 (0.41) MEN1KMT2ALMNAHCRTR1HCRTR2
SCHEMBL27225054 0.87 MEN1 (0.38) MEN1KMT2ALMNAHCRTR1HCRTR2
SCHEMBL31727473 0.87 MEN1 (0.40) MEN1KMT2ALMNAHCRTR1HCRTR2
SCHEMBL29179828 0.87 MEN1 (0.40) MEN1KMT2ALMNAHCRTR1HCRTR2
SCHEMBL31342256 0.87 MEN1 (0.40) MEN1KMT2ALMNAHCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4572755-A2 CDK2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-06-25 — — EP disclosed
US-20240173419-A1 CDK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-05-30 — — US disclosed
WO-2024039901-A2 CDK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2024-02-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240173419-A1 CDK2 DEGRADERS AND USES THEREOF CDK2, CDK20, CDK1 MEN1 2032/4885KMT2A 290/4885LMNA 1186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback